# A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

> **NCT07026123** · — · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Nal-IRI (Onivyde®)-based treatment
- **DRUG:** Other second-line treatment

## Key facts

- **NCT ID:** NCT07026123
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07026123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07026123, "A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07026123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*